Diagnosis and treatment of pulmonary arterial hypertension

Cardiology Clinics

Volumn 22, Issue 3, 2004, Pages 441-452

  Channick, Richard ^a   Williamson, Timothy L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kansas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADRENOMEDULLIN; AMBRISENTAN; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; ILOPROST; NIFEDIPINE; NITRIC OXIDE; OXYGEN; PRASTERONE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE; VERAPAMIL; WARFARIN;

ALTITUDE; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BLOOD FLOW; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ECHOCARDIOGRAPHY; FLUSHING; FUNCTIONAL ASSESSMENT; HEADACHE; HEART CATHETERIZATION; HEART LUNG TRANSPLANTATION; HUMAN; HYPOTENSION; INJECTION SITE; JAW; LEG PAIN; LIFESTYLE; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG PERFUSION; LUNG SURGERY; LUNG TRANSPLANTATION; NAUSEA; NONHUMAN; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RADIOGRAPHY; REVIEW; SIDE EFFECT; SYNCOPE; THORAX PAIN; TREATMENT CONTRAINDICATION; WORLD HEALTH ORGANIZATION;

HUMANS; HYPERTENSION, PULMONARY;

EID: 4043174804     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2004.04.004     Document Type: Review

References (72)

1. Simonneau G., Galiè N., Rubin L., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 43:2004;55-125
2. Meyrick B. The pathology of pulmonary artery hypertension. Clin Chest Med. 22:2001;393
3. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 159:1999;1925
4. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 115:1991;343
5. Raymond R.J., Hinderliter A.L., Willis P.W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 39:2002;1214
6. Kawut S.M., Taichman D.B., Archer-Chicko C.L., et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 123:2003;344
7. Holcomb B.W. Jr., Loyd J.E., Ely E.W., et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest. 118:2000;1671
8. Daily P.O., Dembitzsky W.P., Iversen S., et al. Current early results of pulmonary thromboendarterectomy for chronic pulmonary embolism. Eur J Cardiothorac Surg. 4:1990;117
9. Fedullo P.F., Auger W.R., Kerr K.M., et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 345:2001;1465
10. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 107:1987;216
11. Meyer F.J., Ewert R., Hoeper M.M., et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax. 57:2002;473
12. Bailey C.L., Channick R., Auger W., et al. "High probability" perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med. 162:2000;1974
13. McGoon M.D. The assessment of pulmonary hypertension. Clin Chest Med. 22:2001;493
14. Hinderliter A.L., Willis P.Wt., Long W., et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Am J Cardiol. 84:1999;481
15. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 167:2003;735
16. Cotton C.L., Gandhi S., Vaitkus P.T., et al. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl. 8:2002;1051
17. Wensel R., Opitz C.F., Anker S.D., et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 106:2002;319
18. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 161:2000;487
19. McCaffrey R.N., Dunn L.J. Primary pulmonary hypertension in pregnancy. Obstet Gynecol Surv. 19:1964;567
20. Weiss B.M., Zemp L., Seifert B., et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 31:1998;1650
21. Roberts D.H., Lepore J.J., Maroo A., et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest. 120:2001;1547
22. Group NOTT. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 93:1980;391
23. Rafanan A.L., Golish J.A., Dinner D.S., et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 120:2001;894
24. Frank H., Mlczoch J., Huber K., et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 112:1997;714
25. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 327:1992;76
26. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 114:1998;787
27. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Parent F, et al. Acute vasodilator responsiveness and long-term response to calcium-channel blockers in different forms of pulmonary artery hypertension [abstract A86]. In: Programs and abstracts of the 100th International Conference of the American Thoracic Society. Orlando, Florida: 2004. p. A210.
28. Raffy O., Azarian R., Brenot F., et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 93:1996;484
29. Sitbon O., Humbert M., Jagot J.L., et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 12:1998;265
30. Stewart D.J., Levy R.D., Cernacek P., et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 114:1991;464
31. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 120:2001;1562
32. Davie N., Haleen S.J., Upton P.D., et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 165:2002;398
33. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 358:2001;1119
34. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896
35. McLaughlin V., Sitbon O., Rubin L.J., et al. The effect of first line bosentan on survival of patients with primary pulmonary hypertension. Abstract:2003;American Thoracic Society
36. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 327:1992;70
37. Hinderliter A.L., Willis P.W.T., Barst R.J., et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 95:1997;1479
38. Langleben D., Barst R.J., Badesch D., et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 99:1999;3266
39. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 334:1996;296
40. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 132:2000;425
41. Paramothayan N.S., Lasserson T.J., Wells A.U., et al. Prostacyclin for pulmonary hypertension. Cochrane Database Syst Rev CD002994. 2003
42. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 99:1999;1197
43. Kuhn K.P., Byrne D.W., Arbogast P.G., et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 167:2003;580
44. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 40:2002;780
45. Humbert M., Maitre S., Capron F., et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med. 157:1998;1681
46. Palmer S.M., Robinson L.J., Wang A., et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 113:1998;237
47. McLaughlin V.V., Gaine S.P., Barst R.J., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 41:2003;293
48. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 165:2002;800
49. Hoeper M.M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 342:2000;1866
50. Olschewski H., Ghofrani H.A., Schmehl T., et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med. 132:2000;435
51. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 347:2002;322
52. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 39:2002;1496
53. Barst R.J., Rich S., Widlitz A., et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest. 121:1860;2002
54. Bharani A., Mathew V., Sahu A., et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. 55:2003;55
55. Ghofrani H.A., Schermuly R.T., Rose F., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 167:2003;1139
56. Michelakis E., Tymchak W., Lien D., et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 105:2002;2398
57. Molina J., Lucero E., Luluaga S., et al. Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy. Lupus. 12:2003;321
58. Sastry B.K., Narasimhan C., Reddy N.K., et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. 54:2002;410
59. Ghofrani H.A., Rose F., Schermuly R.T., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 42:2003;158
60. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 136:2002;515
61. Stiebellehner L., Petkov V., Vonbank K., et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest. 123:2003;1293
62. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 360:2002;895
63. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 338:1998;1397
64. Kandler M.A., Von Der Hardt K., Mahfoud S., et al. Pilot intervention: aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther. 306:2003;1021
65. Bonnet S., Dumas-de-La-Roque E., Begueret H., et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A. 100:2003;9488
66. Girgis R.E., Li D., Zhan X., et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 285:2003;H938
67. Petkov V., Mosgoeller W., Ziesche R., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 111:2003;1339
68. Rich S., Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 51:1983;1560
69. Sandoval J., Gaspar J., Pulido T., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 32:1998;297
70. Trulock E., Edwards L., Taylor D., et al. The registry of the International Society for Heart and Lung Transplantation: Twentieth Official Adult Lung and Heart-lung Transplant Report-2003. J Heart Lung Transplant. 22:2003;625
71. Pielsticker E.J., Martinez F.J., Rubenfire M. Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant. 20:2001;1297
72. Physicians American Society for Transplant Physiciano, American Thoracic Society, European Respiratory Society, et al. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med. 158:1998;335